← Back to Search

Bone Graft

Osteocel Plus for Osteoporosis

N/A
Waitlist Available
Research Sponsored by Ahmad Kutkut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3.5 months post-operative of sinus augmentation.
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to histologically and radiographically evaluate the maxillary sinus bone volume and density, with reference to percentage of vital bone present, after four months of grafting with either Osteocel or a cortical-cancellous allograft. 1. To assess the quality and quantity of the maxillary sinus bone prior to the placement of dental implants and subsequent restorations, approximately 20 patients will be randomly assigned to receive an augmentation of the maxillary sinus region using either Osteocel or a cortical-cancellous allograft. 2. With the use of pre-operative and four months post-operative CBCT radiography, the maxillary sinus bone density will be assessed and compared between the individuals receiving Osteocel and the individuals receiving conventional cortical-cancellous allograft material. 3. Histomorphometric analysis will be used to assess, compare and contrast the quality and the quantity of the new vital bone cells generated when using these different graft materials

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.5 months post-operative of sinus augmentation.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.5 months post-operative of sinus augmentation. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Quality of Bone Regeneration (Number of Osteoblasts per histologic section)
Quantity of Bone Regeneration (Linear measurements)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Osteocel PlusExperimental Treatment1 Intervention
Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
Group II: alloOssActive Control1 Intervention
The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bilateral Sinus Augmentation
2017
N/A
~20

Find a Location

Who is running the clinical trial?

Ahmad KutkutLead Sponsor
1 Previous Clinical Trials
~1 spots leftby Dec 2025